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Background.Anaemia is common in inflammatory bowel disease (IBD), frequently resulting from a combination of iron deficiency
and of anaemia of chronic disease (ACD). ACD is characterized by macrophage iron retention induced by proinflammatory
cytokines. Hepcidin is the master inducer of iron accumulation during ACD, and its production is mainly regulated by IL-6
and the novel erythroid hormone erythroferrone (ERFE). This study evaluates whether anti-TNF monoclonal antibodies therapy
modurates hepcidin production and the levels of itsmain regulators, leading to a restoration of iron homeostasis.Methods. Serawere
collected from 21 IBD patients, before each anti-TNF administration, for the first 6 weeks of therapy. Prohepcidin, erythropoietin,
erythroferrone, C reactive protein, interleukin-6, ironmarkers, and haemoglobin levels were measured and clinical activity indexes
were evaluated. Results. Serum prohepcidin, IL-6, CRP, and ferritin were significantly reduced after 6-week treatment; an increase
in serum iron and total transferrin was observed. No changes in the EPO-ERFE axis were found. Remarkably, haemoglobin was
significantly increased. Conclusions. Anti-TNF therapy improves iron metabolism and, subsequently, anaemia in IBD. This effect
appears to be related to the modulation of the cytokine network and specifically IL-6 leading to a relevant decrease of hepcidin, a
master regulator of ACD.
1. Introduction
Anaemia is a common systemic manifestation of inflam-
matory bowel disease (IBD), occurring in 6% to 74% of
patients [1]. Anaemia in IBD is a prototypic combination of
iron deficiency and anaemia of chronic disease, but vitamin
deficiencies andmyelosuppressive drugs, such as thiopurines
and/or methotrexate, may also play a role [2].
Iron deficiency in IBD maybe a consequence of chronic/
recurrent bleeding from ulcerated intestinal mucosa; in
Crohn’s disease (CD), it may also be associated with iron
malabsorption, due to an impaired absorptive function in the
inflamed small bowel [3, 4].
Laboratory tests in iron deficiency anaemia usually depict
a classical panel characterized by low serum levels of iron
and ferritin, reduced transferrin saturation, and increased
transferrin concentration.
On the other hand, anaemia of chronic disease (ACD) is
characterized by normal or increased ferritin levels, as a result
of increased storage and retention of iron within the retic-
uloendothelial system; in fact, during chronic inflammatory
diseases proinflammatory cytokines lead to the activation of
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macrophages which augment their erythrophagocytic activ-
ity and express increased levels of divalent metal transporter-
1 (DMT-1), a transmembrane protein functioning as a major
iron uptaker. Conversely, the macrophage expression of
ferroportin-1, the only known cellular iron exporter, is
reduced, blocking the release of iron from these cells and
ultimately leading to intracellular iron accumulation [5].
Recent data suggest that hepcidin, an acute phase protein
produced by the liver, is amajor regulator of ironmetabolism.
In fact, hepcidin inhibits the function of ferroportin-1,
expressed by macrophages and enterocytes; thus, high levels
of hepcidin favour iron storage in the reticuloendothelial
system and reduce iron absorption from the gut, promoting
the development of ACD [5].
Hepcidin expression is mainly induced by the proin-
flammatory cytokine interleukin-5 (IL-6) and by the bacte-
rial lipopolysaccharide. More recently, a peptide previously
known as Fam 132bhas been recognized to negatively regulate
hepcidin synthesis and named erythroferrone (ERFE) [6]. In
a murine model, it has been shown that, after haemorrhage,
ERFE-mediated suppression of hepcidin allows increased
iron absorption and mobilization from stores. In fact, ERFE
mediates hepcidin downregulation during erythropoiesis and
itis produced by erythroblasts in the bone marrow and in the
spleen in response to erythropoietin (EPO) [6].
Indeed, hepcidin regulation is finely tuned by opposing
stimuli: on one hand by proinflammatory molecules which
enhance its production and lead to ACD during inflamma-
tory/infectious conditions on the other hand, by the EPO-
ERFE axis, which, according to recent data, appears to keep
hepcidin suppressed in order to recover from a hypoxic state
and to restore erythropoiesis.
Among the many pr-inflammatory cytokines, tumour
necrosis factor- (TNF-) 𝛼 plays a major pathogenic role in
immune-mediated disorders such as inflammatory bowel
diseases. Indeed, anti-TNF monoclonal antibodies (namely,
Infliximab and Adalimumab) are effective therapeutic
options in inducing remission in moderate to severe IBD,
throughout the downregulation of several proinflammatory
mediators.
Aim of the study was thus to evaluate whether anti-TNF
agents exert any effect on hepcidin production and on its reg-
ulators, leading to a restoration of normal iron homeostasis in
IBD patients.
2. Patients and Methods
2.1. Patients. IBD patients (16 CD and 5 UC) scheduled to
undergo anti-TNF therapy with Infliximab (9 CD and 5 UC)
or Adalimumab (7 CD) at the Gastroenterology and
Endoscopy Unit of IRCCS Policlinico San Donato were
enrolled, after having read and signed a specific informed
consent. All diagnoses had been confirmed by clinical,
endoscopic, and histologic criteria [7, 8]. In the whole
population, the mean age of the patients was 40 years (range
18–62) and there were 7 men and 14 women. None of
the patients was treated with blood transfusions, iron, or
vitamin supplementations at the moment of enrollment and
in the following weeks. The indications to anti-TNF therapy
Table 1: Demographic and clinical characteristic of enrolled
patients.
Diagnosis CD UC
Number of patients 16 5
Age (mean ± SD) 35.2 ± 13.9 55.6 ± 7.1
Sex (male/female) 5/11 2/3
Location CD
Ileal 1 —
Colonic 4 —
Ileocolonic 11 —
Upper GI involvement 0 —
Extent UC
Proctitis — 0
Left sided colitis — 1
Extensive colitis — 4
Disease behavior CD
Nonstricturing, nonpenetrating (B1) 14 —
Stricturing (B2) 0 —
Penetrating (B3) 0 —
Perianal disease 2
Previous resective surgery 2 —
Concurrent treatment
Mesalazine (# of pts) 1 4
Steroids (# of pts) 6 2
Immunosuppressors (# of pts) 7 1
were corticosteroid-dependent/resistant active disease (19
patients) or perianal disease (2 patients). Disease activity was
assessed using the Harvey-Bradshaw Index (HBI) for CD
patients [9] and the Mayo scores for UC [10].
The demographic and clinical characteristics of the
patients are reported in Table 1.
All patients underwent blood sampling 1 h prior to each
drug administration, with the following schedules: 𝑇
0
, week
2 and week 6 for Infliximab infusions (5mg/kg/infusion);
𝑇
0
, week 2, week 4, and week 6 for Adalimumab injections
(160-80-40-40mg/injection). The two different schedules of
sampling were related to the different induction therapy
regimens characteristic of the two drugs. A reduction of at
least two points in the original HBI or in the partial Mayo
scores (i.e., Mayo score without endoscopic evaluation), by
the end of the induction regimen, was considered indicative
of clinical response to therapy.
2.2. Serum Collection. Whole blood samples were used to
measure whole blood cell count. Peripheral blood was also
collected by venipuncture of an anticubital vein without any
blood stasis using sterilized needles in BD vacutainer SST
II Advance for serum collection. A 3ml blood tube was
used for serum separation after centrifugation at 2500×g for
20min at room temperature. Serumwas stored at−80∘Cuntil
the time of assays.
2.3. Prohepcidin and Iron Status Markers’ Measurement. Pro-
hepcidin, a dosable hepcidin precursor, was measured by
Canadian Journal of Gastroenterology and Hepatology 3
0
2
4
6
8
10
H
ar
ve
y 
Br
ad
sh
aw
 In
de
x
0
5
10
15 p < 0.0001
H
ar
ve
y 
Br
ad
sh
aw
 In
de
x
0
2
4
6
8
Pa
rt
ia
l M
ay
o 
sc
or
e
Pa
rt
ia
l M
ay
o 
sc
or
e
0
2
4
6
8
10
p = 0.2233
CD patients
UC patients
W2 W6 W6
W2 W6 W6
T0T0
T0 T0
Figure 1: Clinical activity indexes throughout anti-TNF therapy. Harvey-Bradshaw Index and partial Mayo score were calculated before each
drug administration to CD (𝑁 = 16) and UC (𝑁 = 5) patients, respectively, undergoing anti-TNF therapy. Statistical analysis was performed
using Student’s 𝑡-test for paired data. Data are presented as single data point or as mean ± SEM.
means of a commercially available ELISA kit (DRG, Marb-
urg-Germany).
Serum ferritin was determined by a solid-phase two-site
chemiluminescent-immunometric assay. Transferrin and C
reactive protein (CRP) levels were measured by an immuno-
turbidimetric assay and iron by a colorimetric assay (Roche
Diagnostic, Mannheim, Germany).
2.4. Erythroferrone (ERFE), Erythropoietin (EPO), and
Interleukin- (IL-) 6 Concentration. Erythroferrone (ERFE)
and interleukin- (IL-) 6 levels were measured by means of
commercial sandwich ELISA kits according to the manu-
facturers’ instructions (Cusabio Biotech, China; Abnova, UK
resp.).
Erythropoietin was determined by IMMULITE 2000
EPO a chemiluminescent-immunometric assay (Siemens
Healthcare, Italy).
2.5. Statistical Analysis. Statistical analysis was performed by
means of paired Student’s 𝑡-test and Pearson’s correlation test.
2.6. Ethical Requirements. The Internal Review Board of
the local Ethical Committee approved the study (Ethical
Committee Protocol number 2025, ASL Milano-2, approved
on June 14, 2007), in accordance with the 1964 Declaration of
Helsinki.
3. Results
3.1. Clinical Response to Anti-TNF Therapy. In order to
evaluate the response to anti-TNF therapy we calculated HBI
and partialMayo scores for CD andUC patients, respectively,
at baseline, that is, before the first Infliximab or Adalimumab
administration (𝑇
0
), and at the end of the observation period,
that is, before the week 6 of drug administration schedule
(W6). All patients affected by CD showed a clinical response
to anti-TNF infusion, that is, a reduction of at least two points
in the original HBI (mean HBI 6.87 ± 0.63 versus 1.93 ± 0.41
at 𝑇
0
and W6, resp.; 𝑝 < 0.0001) (Figure 1 and Table 2).
Three out of five UC patients treated with Infliximab had
a complete clinical response (final partial Mayo = 0), whereas
two did not achieve any benefit from the aforementioned
therapy (Figure 1, Table 2).
3.2. Pharmacologic Block of TNF, Dampening Systemic Inflam-
mation, Reduces Prohepcidin SerumLevels. After establishing
the overall good response to therapy, we wanted to eval-
uate whether or not it corresponded to any change in the
expression of a master regulator of iron metabolism, that
is, hepcidin. Therefore, we measured serum concentration
of prohepcidin, a circulating precursor of hepcidin, which
is easily detected in the serum and correlates with actual
hepcidin levels [11, 12]. Blood samples were collected before
each drug administration, throughout the therapy schedule,
from 𝑇
0
to W6.
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Table 2: Patients’ clinical scores.
CD patients
Pts # 𝑇
0
HBI W2 HBI W4 HBI W6 HBI
IFX treatment
1 11 5 — 2
2 8 3 — 1
3 8 2 — 1
4 7 4 — 3
5 6 3 — 0
6 5 2 — 2
7 8 3 — 3
8 3 2 — 1
9 2 0 — 0
ADA treatment
10 10 8 8 5
11 10 5 7 5
12 3 1 0 0
13 7 2 2 2
14 6 4 4 3
15 9 1 0 0
16 5 4 3 3
UC patients
Pts # 𝑇
0
MS 𝑇
0
PMS W2 PMS W4 PMS W6 PMS
IFX treatment
17 7 5 0 — 0
18 7 5 7 — 8
19 9 7 2 — 7
20 9 7 0 — 0
21 7 4 0 — 0
HBI, Harvey-Bradshaw Index; MS, Mayo score; PMS, partial Mayo score.
When all patients (both CD and UC) treated with anti-
TNF were analyzed, serum levels of prohepcidin at W6
were significantly decreased, compared with levels measured
before 𝑇
0
administration (139.42 ± 18.96 versus 94.14 ±
9.19 ng/ml, 𝑝 = 0.0048); consistently, circulating levels of
other acute phase proteins, such as ferritin andCRP, were also
reduced (68.19±18.23 versus 37.48±13.22 ng/ml, 𝑝 = 0.0223
and 1.80 ± 0.42 versus 0.53 ± 0.11mg/dl, 𝑝 = 0.0036, resp.).
All these data are reported in Figure 2.
When stratifying patients according to disease, significant
reductions of prohepcidin, CRP and ferritin were detected in
CD patients (𝑝 = 0.0231, 𝑝 = 0.0099, and 𝑝 = 0.0103, resp.)
(Figure 3), whereas UC patients only showed a trend towards
a decrease of prohepcidin and CRP (Figure 4).
When different drugs were considered, prohepcidin and
CRP were significantly reduced in IFX treated patients (𝑝 =
0.0318 and𝑝 = 0.0112, resp.), while ferritin showed a nonsta-
tistically significant decrease (𝑝 = 0.0651) (Supplemen-
tary Figure 1 in Supplementary Material available online at
https://doi.org/10.1155/2017/6843976); on the other hand, in
the ADA treatment group whereas we demonstrated reduc-
tions of all the aforementioned parameters, none of these
reached the statistical significance (Supplementary Figure 2).
3.3. Anti-TNF Administration Restores Iron Availability and
Usage in IBD Patients. As anti-TNF therapy reduced cir-
culating prohepcidin and ferritin, we detected a substan-
tial improvement of iron homeostasis; in fact, following
Infliximab or Adalimumab administration, circulating iron
increased significantly from 𝑇
0
to W6 (37.71 ± 2.77 ver-
sus 45.14 ± 3.78 𝜇g/dl, 𝑝 = 0.0501) (Figure 5). We also wit-
nessed a significant increase of total transferrin (201.5 ± 8.12
versus 241.2 ± 10.99mg/dl, 𝑝 = 0.0048), which is consistent
with the reduction of systemic inflammatory activation (Fig-
ure 5). No significant changes in transferrin saturation were
observed (Figure 5). Remarkably, haemoglobin levels signif-
icantly increased when comparing baseline values at 𝑇
0
with
those observed at W6 (11.44 ± 0.33 versus 12.14 ± 0.29 g/dl,
𝑝 = 0.0137), as reported in Figure 5, suggesting an increase in
the availability and usage capacity of circulating iron. When
we analyzed data clustering patients for disease, transferrin
and haemoglobin levels were significantly increased in CD
patients (𝑝 = 0.0033 and 𝑝 = 0.0115, resp.) (Figure 3); inst-
ead, inUCpatients, no significant changes in circulating iron,
transferrin, and haemoglobinwere detected (Figure 4).When
stratifying patients for drug used, all those parameters were
significantly increased in IFX treated patients (𝑝 = 0.0239,
𝑝 = 0.0070, and 𝑝 = 0.0048 for iron, transferrin, and haemo-
globin, resp.) (Supplementary Figure 1), but not in ADA
group (Supplementary Figure 2).
3.4. Anti-TNF Blockade Reduces IL-6 Levels but Does Not
Modulate EPO-ERFE Axis. We investigated the role of anti-
TNF drug administration in modulating the main regulators
of hepcidin production; thus, we measured IL-6, EPO, and
ERFE circulating levels before and following the first 6
weeks of Infliximab/Adalimumab therapy. IL-6 levels were
significantly reduced from𝑇
0
toW6 (14.03±2.15 versus 9.82±
0.97 pg/ml, 𝑝 = 0.0295) (Figure 6). Significant reductions
were still observed when considering only UC patients or
only ADA treated patients (𝑝 = 0.0476 and 𝑝 = 0.0103,
resp.) (Figure 4 and Supplementary Figure 2). No changes
were detected in EPO, neither in ERFE levels in our patients
(Figure 6).Therefore, while downregulating IL-6 production,
in our cohort, anti-TNF did not appear to influence the EPO-
ERFE axis.
Then, we tried to analyze the potential correlation
between the circulating levels of IL-6, prohepcidin, and
CRP. No significant correlation was detected when pool-
ing together all patients or CD patients alone; however,
when considering UC patients with a response to anti-
TNF-therapy a statistically significant correlation between
IL-6 and prohepcidin and between CRP and prohepcidin
have been observed (𝑝 < 0.0001, 𝑟 = 0.95 and 𝑝 = 0.029,
𝑟 = 0.72, resp.) (Figures 7 and 8). This may suggest a greater
relevance of the IL-6-prohepcidin axis in UC or more simply
a greater homogeneity of patients and disease features in UC,
compared to CD.
4. Discussion
Anaemia is among themost frequent extraintestinal manifes-
tations of IBDoccurring in 6% to 74%of patients [1] and it has
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Figure 2: Prohepcidin and acute phase protein levels during anti-TNF therapy. Serum samples were collected before each anti-TNF
administration and prohepcidin, ferritin, and CRP circulating levels measured. Statistical analysis was performed using Student’s 𝑡-test for
paired data. Data are presented as single data point or as mean ± SEM.
been suggested that anaemia is probably too common to be
specifically recognized as a complication of IBD but it should
be often seen as a consistent clinical feature of it [13].
The impact of anaemia on the quality of life in general
patients and particularly in patients affected by IBD is
profound [14, 15]. In particular, anaemia can debilitate IBD
patients as much as abdominal pain or diarrhea and it may
impair quality of life even in the absence of anaemia-specific
symptoms [16]. Remarkably, the quality of life in IBD patients
with anaemia may be as low as in anaemic patients with
advanced cancer [16].
The mechanisms by which anaemia may develop are
multiple, encompassing iron deficiency, chronic anaemia of
inflammation, and vitamin deficiencies; in general, the sys-
tem involving hepcidin and ferroportin expression is thought
to play a major role in iron homeostasis and subsequent
anaemia. Some studies have already been performed focusing
on hepcidin levels in IBD. However, the data resulting from
these studies have been very heterogeneous, with some
indicating high hepcidin levels in CD and UC compared to
controls [17], other showing no significant differences [18],
still other reporting low levels in IBD, regardless of iron
deficiency anaemia [19, 20]. These data may be explained
considering the great heterogeneity among IBD patients
included in these studies in terms of disease activity, clin-
ical features, and iron status; in fact, it is worthy of note
that whereas inflammatory states increase the production
of hepcidin, its levels are drastically reduced during iron
deficiency conditions [21].Most recent data show that, in IBD
patients, hepcidin appears to be a reliable marker for ACD
[22], while not being an optimal indicator of IBD clinical
activity [23]. As a matter of fact, the concomitant existence
6 Canadian Journal of Gastroenterology and Hepatology
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Figure 3: Prohepcidin and acute phase protein levels during anti-TNF therapy in CD patients. Blood samples were collected before each anti-
TNF administration and parameters measured. Statistical analysis was performed using Student’s 𝑡-test for paired data. Data are presented as
single data point or as mean ± SEM.
of intestinal inflammation and iron deficiency may lead to a
great variability in hepcidin levels in IBD patients.
Therefore, given the prevalence of anaemia and its impact
on the quality of life in IBD,we studied prohepcidin levels and
iron homeostasis and their potential modifications induced
by anti-TNF treatment in a group of patients with IBD. Inter-
estingly, since we compared prohepcidin circulating levels
from single patients at different timepoints, our methodolog-
ical approach allowed us to overcome the great interpatients
variability of the circulating levels of this protein.
In our series, when all patients with Crohn’s disease
and ulcerative colitis treated with anti-TNF were analyzed,
serum prohepcidin was significantly decreased before W6
administration compared with baseline levels at 𝑇
0
. Overall,
the decrease in serum prohepcidin levels paralleled the
decrease in the clinical activity indexes, indicating control
of inflammation. These observations were supported when
patients were divided into the two diagnoses although the
small number of UC patients enrolled and the more hetero-
geneous clinical responses were probably responsible for not
reaching a statistical significance. Indeed, the data obtained
onUCpopulationmay be useful to determine the sample size
for future studies, focused on UC.
Consistently with the decrease in clinical activity indexes,
we observed a significant reduction of CRP and ferritin, two
acute phase proteins. These data suggest a strong correlation
between abnormal iron homeostasis, inflammation, and dis-
ease activity in our patients with inflammatory bowel disease.
As anti-TNF therapy reduced circulating prohepcidin
and ferritin, we detected a substantial improvement of iron
homeostasis, associated with an increase in haemoglobin
production.
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Figure 4: Prohepcidin and acute phase protein levels during anti-TNF therapy in UC patients. Blood samples were collected before each anti-
TNF administration and parameters measured. Statistical analysis was performed using Student’s 𝑡-test for paired data. Data are presented as
single data point or as mean ± SEM.
This observation is in agreement with previous reports
performed in IBD and other chronic inflammatory condi-
tions, where anti-TNF therapy ameliorated patients’ anaemia;
as an instance, it has been shown that anaemic patients
affected by CD increase their haemoglobin levels, when
obtaining a clinical response to Infliximab administration
[24]. In addition, Davis et al. demonstrated a dose-dependent
improvement of anaemia in a cohort of rheumatoid arthritis
patients undergoing Infliximab infusions [25]. More recently,
Bes et al. performed a similar study in ankylosing spondylitis,
again showing a significant improvement of haemoglobin
levels in patients treated with both Infliximab and Adali-
mumab, compared to those treated with nonbiological agents
[26]. Overall, authors predominantly ascribed this beneficial
effect to the abrogation of TNF-mediated suppression of bone
marrow erythropoiesis; however, in these studies, the possible
interplay between TNFmodulation and hepcidin production
and its role in the regulation of anaemia of chronic disease
were not taken into account.
As a matter of fact, since it has been largely demon-
strated that hepcidin acts as an acute phase reactant, it is
not surprising that its levels may be deeply influenced by
potent anti-inflammatory agents such as anti-TNF drugs.
Indeed, we believe that our data strongly suggest that the
anti-inflammatory action of anti-TNF is responsible for the
beneficial effect on haemoglobin levels through the inhibition
of hepcidin production. In fact, hepcidin production is
increased up to 100-fold in anaemia of inflammation. More-
over, it has been recently demonstrated on an animalmodel of
colitis that the induction of intestinal inflammation promotes
hepcidin production, in a microbiota dependent-fashion
[27]. TNF is a pivotal cytokine involved in the pathogenesis
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Figure 5: Modulation of iron markers and haemoglobin following anti-TNF therapy. Blood samples were collected before each anti-TNF
administration (𝑁 = 21/time point) and circulating iron, transferrin, andhaemoglobin levelsmeasured. Transferrin saturationwas calculated,
as well. Statistical analysis was performed using Student’s 𝑡-test for paired data. Data are presented as single data point or as mean ± SEM.
of anaemia of chronic disease, by inhibiting proliferation
and differentiation of erythroid progenitor cells and by
inducing apoptosis of red cells precursors; however, a wealth
of data clearly demonstrates that TNF is a potent inhibitor
of hepatocyte production of hepcidin [2, 28]. Some indirect
pathway might be hypothesized in order to explain our
data. Therefore, we tried to obtain some insights on which
hepcidin regulation pathway could be involved in mediating
anti-TNF effects in our series. Thus, we measured the cir-
culating levels of IL-6, erythropoietin, and erythroferrone.
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Figure 6: IL-6, EPO, and ERFE levels before and after 6 weeks of anti-TNF therapy. Sera were collected before each anti-TNF administration
(𝑁 = 21/time point) and IL-6, EPO, and ERFE levels measured. Statistical analysis was performed using Student’s 𝑡-test for paired data. Data
are presented as single data point or as mean ± SEM.
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Figure 7: Correlation between IL-6 andCRP versus prohepcidin inCDpatients. Statistical analysis was performed using Pearson’s correlation
coefficient.
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Figure 8: Correlation between IL-6 andCRP versus prohepcidin inUCpatients. Statistical analysis was performed using Pearson’s correlation
coefficient.
In fact, IL-6 was shown to be a prominent inducer of
hepcidin. In healthy volunteers infused with IL-6, urinary
excretion of hepcidin was increased several folds within two
hours after infusion [28]. It has also been shown that TNF
potently induces IL-6 production by macrophages, poten-
tiating inflammatory responses. Conversely, several papers
demonstrate that anti-TNFmonoclonal antibody administra-
tion potently and promptly reduces circulating levels of IL-
6 and other proinflammatory cytokines [29–31]. Therefore
it might be hypothesized that the modulation of prohep-
cidin levels we observed following anti-TNF administration
is obtained throughout an indirect pathway, likely involv-
ing anti-TNF-mediated downregulation of known hepcidin-
inducing cytokines, such as IL-6. Supporting this hypothesis,
Emery et al. demonstrated that Golimumab, another anti-
TNF monoclonal antibody, promoted a significant reduction
of urinary hepcidin in rheumatoid arthritis patients. This
effect correlated with a consensual decrease of CRP and,
remarkably, of IL-6 [32]. Consistently, we detected in our
patients a significant reduction of IL-6 levels, suggesting that
the TNF-IL-6 axis may be relevant in modulating hepcidin
production during anti-TNF therapy. Nonetheless, our data
are primarily descriptive in nature; therefore, additional “in
vitro” and “ex vivo” observations, aimed at mechanistically
dissecting the TNF-IL-6-hepcidin axis, are needed to confirm
the importance of this pathway during anti-TNF therapy.
ERFE is a newly identified hormone, produced by ery-
throblasts, following EPO stimulus, which blocks hepcidin
production [6, 33, 34]. ERFE has a role in the recovery from
anaemia of inflammation, as demonstrated in amousemodel
of ACD induced by injection of heat-killed Brucella abortus;
in this model, through the suppression of hepcidin, ERFE
contributes to the recovery from ACD [33].
EPO is a growth factor essential for erythroid progenitors
and precursors and is produced in the kidney in response
to hypoxia. Interestingly, Bergamaschi et al. demonstrated an
increase of EPO, after Infliximab treatment in IBD patients
[24]; thus, we anticipated anti-TNF blockade to restore EPO
production and induce ERFE, further reducing hepcidin
levels. Unexpectedly, the measurement of EPO and ERFE in
our cohort did not show significant changes after Infliximab
and Adalimumab therapies. This may be due to the fact that
our patients, overall, showed mild anaemia; thus, they may
not have been exposed to a hypoxic stimulus, substantial
enough to significantly increase EPO levels. Indeed, further
studies, on a broader population, are warranted to evaluate
the relevance of the erythropoietin-erythroferrone axis in
IBD patients, not only in the context of anti-TNF therapy.
Taken together, our data show that anti-TNF therapy
significantly improves iron metabolism and, subsequently,
anaemia in IBD.This effect appears to be primarily related to
the modulation of the cytokine network, leading to a relevant
decrease of hepcidin, amaster regulator of anaemia of chronic
disease. Therefore, in IBD patients anti-TNF agents seem
to play a role in ameliorating anaemia of chronic disease
during a 6-week treatment; on the other hand, in a long-
term treatment, anti-TNF therapy may also improve iron
deficiency anaemia, throughout the induction of mucosal
healing. However, there is still the possibility that clinical
improvement among IBD patients is not necessarily linked
to the restoration of iron homeostasis.
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